GlycoMimetics Inc (GLYC)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

9708 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850

GlycoMimetics, Inc. develops molecule drugs. The company offers research, development, and commercialization of specialized small molecule drug compounds for the treatment of blood cancers and certain inflammatory conditions.

Data based on most recent fiscal year report
Market Cap545.663 Million Shares Outstanding34.34 Million Avg Volume1.454 Million
1-Yr BETA vs S&P TR1.64 Current Ratio15.57 Quick Ratio15.57
View SEC Filings from GLYC instead.
Q1 2019 All Institutions Hedge Funds 1
To trade GLYC now:
Filers who had this stock in their top 10: 1 0 (0.0%)
13F Filers holding this stock: 79 11 (1.12%)
Aggregate 13F shares on 03/31/2019: 45.47 Million 3.37 Million
Aggregate 13F shares on 12/31/2018: 45.206 Million 3.511 Million
Percent change: 0.58% -4.01%
Funds creating new positions: 11 2
Funds Adding to an existing position: 32 3
Funds closing out their position: 12 5
Funds reducing their position: 23 5
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GLYC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GOLDBERG MARK ALAN

  • Director
0 2019-06-30 1

SANDELL SCOTT D

  • 10% Owner
7,225,676 2019-06-24 0

BARRIS PETER J

  • 10% Owner
7,225,676 2019-06-24 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
6,526,004 2019-06-19 0

PEARSON TIMOTHY R

  • Director
0 2019-06-11 1

BARRETT M JAMES

  • Director
0 2019-05-30 0

KOENIG SCOTT

  • Director
34,246 2019-05-28 1

JUNIUS DANIEL M

  • Director
0 2019-05-17 1

ANDREWS PATRICIA S

  • Director
0 2019-05-17 1

JACKSON SCOTT THOMAS

  • Director
0 2019-05-17 3

KING RACHEL K.

  • Director
86,000 2019-03-27 1

GIRARD ARMAND SVP, STRATEGY & CORPORATE DEV

  • Officer
0 2019-03-01 1

HAHN BRIAN M. SVP FINANCE, CFO

  • Officer
0 2019-01-17 1

MAGNANI JOHN L. SVP OF RESEARCH, CSO

  • Officer
  • Director
0 2019-01-17 2

THACKRAY HELEN M. SVP CLINICAL DEVELOPMENT, CMO

  • Officer
0 2019-01-17 1

NEW ENTERPRISE ASSOCIATES 10 L P

NEA PARTNERS 10 L P

  • 10% Owner
4,995,664 2018-05-10 0

BALDWIN JOHN J.

  • Director
1,210 2016-06-29 0

TOP FRANKLIN H JR

  • Director
0 2016-05-17 0

HENOS MICHAEL A

  • Director
0 2015-07-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments